Multiple First-in-Class Therapeutics In Development for The Treatment of Neuropsychiatric & Neurological Disorders
Our novel substance use disorder (SUD) therapeutic candidates’ mechanisms of action target multiple receptors that are highly implicated in craving, stress-induced relapse and insomnia to provide potential wholesome treatment.
Hager’s novel Alzheimer Disease (AD) therapeutic candidates’ mechanisms of action simultaneously target key neuromodulator circuits which regulate the interconnected disrupted sleep architecture, impaired glymphatic clearance, neurodegeneration and psychotic aspects of the disease.
Hager’s novel Alzheimer Disease (AD) therapeutic candidates’ mechanisms of action simultaneously target key neuromodulator circuits which regulate the interconnected disrupted sleep architecture, impaired glymphatic clearance, neurodegeneration and psychotic aspects of the disease.
Contact us with inquiries for collaboration, partnering or licensing and Clinical development